StockData
Repligen Corp logo

Repligen Corp (RGEN) stock

RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30132% above fair value
$172.67+10.49 (+6.47%)

Close on Nov 18, 2026Market cap $11.04BP/E –Yield –

Repligen revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Repligen's revenue for the twelve months ending Sep 30, 2026 was $805.61M, up 13.8% year over year. For fiscal 2025 it was $738.26M, up 16.4% from the year before. Over ten years it grew 24.3% a year on average. The highest annual figure on record is $801.54M in fiscal 2022.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$738.26M+16.4%
FY2024Dec 31, 2024$634.44M+0.3%
FY2023Dec 31, 2023$632.36M-21.1%
FY2022Dec 31, 2022$801.54M+19.5%
FY2021Dec 31, 2021$670.53M+83.1%
FY2020Dec 31, 2020$366.26M+35.5%
FY2019Dec 31, 2019$270.25M+39.3%
FY2018Dec 31, 2018$194.03M+37.4%
FY2017Dec 31, 2017$141.24M+35.1%
FY2016Dec 31, 2016$104.54M+25.1%
FY2015Dec 31, 2015$83.54M+31.5%
FY2014Dec 31, 2014$63.55M-6.8%
FY2013Dec 31, 2013$68.17M+149.8%
FY2011Mar 31, 2011$27.29M+30.1%
FY2010Mar 31, 2010$20.97M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$209.31M+10.9%
Q2 FY2026Jun 30, 2026$204.13M+11.9%
Q1 FY2026Mar 31, 2026$194.26M+14.8%
Q4 FY2025Dec 31, 2025$197.91M+18.1%
Q3 FY2025Sep 30, 2025$188.81M+21.9%
Q2 FY2025Jun 30, 2025$182.37M+14.8%
Q1 FY2025Mar 31, 2025$169.17M+10.4%
Q4 FY2024Dec 31, 2024$167.55M+0.6%
Q3 FY2024Sep 30, 2024$154.87M+9.7%
Q2 FY2024Jun 30, 2024$158.84M-0.2%
Q1 FY2024Mar 31, 2024$153.18M-7.4%
Q4 FY2023Dec 31, 2023$166.62M-10.8%
Q3 FY2023Sep 30, 2023$141.19M-29.7%
Q2 FY2023Jun 30, 2023$159.17M-23.3%
Q1 FY2023Mar 31, 2023$165.38M-19.9%
Q4 FY2022Dec 31, 2022$186.76M+0.1%
Q3 FY2022Sep 30, 2022$200.74M+12.6%
Q2 FY2022Jun 30, 2022$207.63M+27.4%
Q1 FY2022Mar 31, 2022$206.40M+44.5%
Q4 FY2021Dec 31, 2021$186.52M+71.7%
Q3 FY2021Sep 30, 2021$178.22M+89.5%
Q2 FY2021Jun 30, 2021$162.96M+86.3%
Q1 FY2021Mar 31, 2021$142.84M+87.7%
Q4 FY2020Dec 31, 2020$108.65M+56.4%
Q3 FY2020Sep 30, 2020$94.06M+35.4%
Q2 FY2020Jun 30, 2020$87.46M+23.7%
Q1 FY2020Mar 31, 2020$76.09M+25.5%
Q4 FY2019Dec 31, 2019$69.47M+33.8%
Q3 FY2019Sep 30, 2019$69.45M+40.2%
Q2 FY2019Jun 30, 2019$70.69M+48.1%
Q1 FY2019Mar 31, 2019$60.63M+35.3%
Q4 FY2018Dec 31, 2018$51.94M+24.8%
Q3 FY2018Sep 30, 2018$49.53M+35.4%
Q2 FY2018Jun 30, 2018$47.73M+47.1%
Q1 FY2018Mar 31, 2018$44.83M+46.6%
Q4 FY2017Dec 31, 2017$41.61M+62.5%
Q3 FY2017Sep 30, 2017$36.58M–
Q2 FY2017Jun 30, 2017$32.46M–
Q1 FY2017Mar 31, 2017$30.59M–
Q4 FY2016Dec 31, 2016$25.60M–

More Repligen figures

See a number that looks wrong?